Table 3.

Association between lowering low-density lipoprotein cholesterol (LDL-C) to clinically recommended levels and CV outcomes for each subgroup.

CohortRA Plus General Controls
RA patients, n = 1522
RA Plus OA Controls
RA patients, n = 1746
Patients with RAHR (95% CI)pHR (95% CI)p
Lowered LDL-C (vs not lowered)*0.72 (0.49–1.07)0.1040.70 (0.49–1.00)0.053
Lowered LDL-C (vs not lowered)§0.68 (0.46–1.02)0.0600.67 (0.46–0.96)0.028
General controls, n = 6511OA controls, n = 2554
Non-RA patientsHR (95% CI)pHR (95% CI)p
Lowered LDL-C (vs not lowered)*0.83 (0.63–1.09)0.1790.93 (0.65–1.31)0.659
Lowered LDL-C (vs not lowered)§0.72 (0.55–0.95)0.0210.76 (0.53–1.07)0.118
  • * Results from univariable analyses.

  • § Results from multivariable analyses adjusting for age, sex, hypertension, antihypertensive medication use, smoking, and diabetes. CV: cardiovascular; RA: rheumatoid arthritis; OA: osteoarthritis.